Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Morphotek licenses HMIís anti-cancer antibody
March 2008
SHARING OPTIONS:

EXTON, Pa.óMorphotek recently announced a licensing agreement with Human Monoclonals International Inc. (HMI) for exclusive rights to a human monoclonal IgM antibody that is specific to a cancer cell surface antigen. Morphotek will apply its proprietary Morphodoma antibody technology and know-how with the goal of developing an optimized lead therapeutic monoclonal antibody. "This agreement provides yet another important addition to our therapeutic antibody portfolio," says Nicholas Nicolaides, Ph.D., president and CEO of Morphotek. "Our antibody optimization and development expertise will enable the further development of this promising antibody."
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.